

# SUVEN Life Sciences Ltd



## News Release

### Suven's half yearly revenues increase by 10%, R&D spent at 26% of Revenue

HYDERABAD, INDIA (Oct' 30, 2007) – SUVEN LIFE Science's Board of Directors meeting held today in Hyderabad announced the results that the revenue increased by 10% to Rs. 5889 lacs for the six months ending Sep' 2007 compared to Rs. 5359 lacs for the corresponding previous period. PAT stood at Rs. 431 lacs compared to Rs. 457 for the corresponding previous period.

The segmental revenue for the first six months from DDDSS increased by 84% to Rs.1008 lacs from Rs.548 lacs. However, there is reduction in CRAMS revenue for the six months from Rs. 4796 lacs to Rs. 4646 lacs, by 3%.

For the 2<sup>nd</sup> quarter ending Sep' 2007, the revenues increased by 7% to Rs.2991 lacs compared to the corresponding previous quarter of Rs.2797 lacs. The PAT stood at Rs.116 lacs compared to Rs.249 lacs for the corresponding previous quarter.

Suven's major thrust on innovative R&D in Drug Discovery continues with a total expenditure (revenue & capital) of Rs 1543 lacs recording about 26% of revenue for six months.

Suven Life Sciences is a Hyderabad based Life Sciences Company a **Collaborative Research Partner (CRP)** since 2006 in **Drug Discovery** for global pharma major is a pioneer in **Contract Research and Manufacturing Services (CRAMS)** since 1995 and **Drug Discovery Development Support Services (DDDSS)** since 2005. Suven has been involved in development of path breaking technologies for global pharma companies for more than a decade.

A focused provider of DDDSS for development of New Chemical Entities to life sciences companies, Suven's commitment to protection of intellectual property, maximization of return on R&D investments for collaborative research partners, ability to offer full spectrum of services from discovery to market launch and provide technologies and expertise in different therapeutic areas. Suven has R&D strength of more than 255 professionals with the state of the art infrastructure for Drug Discovery and development activities and the front end project management services from New Jersey, USA. For more information on Suven, please visit our Web site at <http://www.suven.com>

#### **Risk Statement:**

***Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive;***